About 17 results found for searched term "Prostaglandin B1" (0.171 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41911 | Prostaglandin B1 | Prostaglandin Receptor |
| Prostaglandin B1 (PGB1) is a metabolite of Prostaglandin E1. | ||
| M2471 | Bromfenac Sodium | COX |
| Bromfenac is a nonsteroidal anti-inflammatory compound (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. | ||
| M5401 | Prostaglandin E1 (Alprostadil) | Prostaglandin Receptor |
| Alprostadil; PGE1 | ||
| Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, which induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases. | ||
| M10499 | FPL 62064 | Lipoxygenase |
| FPL62064 | ||
| FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and prostaglandin synthetase (cyclooxygenase, COX) with IC50 of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and seminal vesicle prostaglandin synthetase, respectively. | ||
| M10791 | BAY-1316957 | Prostaglandin Receptor |
| BAY-1316957 is a potent, selective, orally active antagonist of the prostaglandin E2 receptor subtype 4 (EP4-R) against human EP4-R IC50 15.3 nM. BAY-1316957 has excellent drug metabolism and pharmacokinetic properties and can be used in the study of endometriosis. | ||
| M10795 | BGC-20-1531 free base | Prostaglandin Receptor |
| PGN 1531 free base | ||
| BGC-20-1531 (PGN 1531) free base is a potent selective prostaglandin EP4 receptor antagonists, pKB The value is 7.6. BGC-20-1531 free base has the potential to study migraines. | ||
| M10803 | Butaprost | Prostaglandin Receptor |
| Butaprost is a selective prostaglandin E receptor (EP2) agonist for murine EP2 receptors EC50 The value is 33 nM,Ki The value is 2.4 μM. Butaprost is less active against rodents EP1, EP3 and EP4 receptors. Butaprost mitigates fibrosis by obstructing TGF-β/Smad2 signaling. | ||
| M10807 | CJ-42794 | Prostaglandin Receptor |
| CJ-042794 | ||
| CJ-42794 is a selective prostaglandin receptor EP4 antagonist that inhibits [3H]-PGE2 binding to EP4 receptors with an average pKi of 8.5 and is more than 200 times more selective than EP1, EP2 and EP3. | ||
| M10842 | KAG-308 | Prostaglandin Receptor |
| KAG-308 is an effective, selective, orallyable EP4 receptor (a subtype of prostaglandin E2 receptor) agonist that inhibits colitis, promotes tissue mucosal healing, and effectively inhibits the production of TNF-α. KAG-308 for human EP4 receptors Ki value and EC50 The values were 2.57 nM and 17 nM, respectively, which were more selective than EP1, EP2, EP3, and IP receptors. | ||
| M58604 | Vipoglanstat | PGE synthase |
| BI 1029539; GS-248; OX-MPI | ||
| Vipoglanstat (BI 1029539) is an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1; IC50 = ≤0.5 nM in isolated human whole blood). Vipoglanstat reduces LPS-induced increases in the influx of neutrophils and levels of cytokines in bronchoalveolar lavage fluid (BALF), as well as the expression of PTGES, the gene encoding mPGES-1, Cox2, and Icam1 in the lung parenchyma, in a human PTGES knock-in mouse model of acute lung injury when administered at a dose of 30 mg/kg. | ||
| M20536 | Setipiprant (ACT-129968, KYTH-105) | Immunology/Inflammation |
| Setipiprant(ACT-129968, KYTH-105) is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2) that that has been shown to have greater specificity for DP2 (CRTH2) than for DP1. | ||
| M21029 | MRE-269 | Immunology/Inflammation |
| ACT-333679 | ||
| MRE-269 (ACT-333679) is a prostaglandin I2 (IP) receptor agonist with a binding affinity for the human IP receptor that is 130-fold greater than that for other human prostanoid receptor. | ||
| M22519 | Prostaglandin A2 | Metabolite/Endogenous Metabolite |
| PGA2; Medullin | ||
| Prostaglandin A2 (PGA2) is a endogenous metabolite derived from arachidonic acid, it plays a vital role in the induction of apoptosis. Prostaglandin A2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase. Prostaglandin A2 induces p53-dependent apoptosis. | ||
| M30068 | Latanoprost acid | Prostaglandin Receptor |
| Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes. | ||
| M31252 | 8,11,14-Eicosatriynoic acid | Others |
| 8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. | ||
| M56389 | (E)-KME-4 | PGE synthase |
| (E)-KME-4 is a potent inhibitor of prostaglandin synthetase (PGS) with an IC50 of 0.28 μM; also inhibits 5-lipoxygenase with an IC50 of 1.05 μM. | ||
| M56309 | 13,14-Dihydro-15-keto prostaglandin D2 | Prostaglandin Receptor |
| 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
